Literature DB >> 9247255

Metastatic variants derived following in vivo tumor progression of an in vitro transformed squamous cell carcinoma line acquire a differential growth advantage requiring tumor-host interaction.

Z Chen1, C W Smith, D Kiel, C Van Waes.   

Abstract

The purpose of this study was to develop an experimental model of squamous cell carcinoma that can be used to identify molecular and immunologic changes associated with primary events in malignant transformation, and those associated with metastatic tumor progression in the presence of host homeostatic and immunologic factors. Metastatic variants were derived following in vivo tumor progression of the in vitro transformed squamous cell carcinoma line Pam 212. The parental and metastatic cell lines exhibited similar morphologic features and molecular markers of an epithelial lineage, including an epithelial morphology in culture, cell surface expression of integrin alpha6beta4, and expression of mRNA of cytokeratins K6 and K14. When the growth and metastatic phenotype of the parental and reisolate cell lines was compared, the reisolate cell lines were found to exhibit a greater rate of growth and incidence of metastasis than the parental cell line when reimplanted in vivo. The difference in the growth rate of the parental cell line and the variants observed in vivo was not detected when growth of these lines was compared in vitro, suggesting that the growth advantage and selection of these variants requires tumor-host interaction. The metastatic variants exhibited a similar growth advantage in normal immunocompetent and SCID Balb/c mice, indicating that the growth advantage in vivo is not due to T or B lymphocyte-dependent immune factor(s). We conclude that metastatic variants derived following in vivo tumor progression of an in vitro transformed squamous cell carcinoma line exhibit a differential growth advantage in vivo that requires the host environment. Comparison of these in vitro transformed and in vivo derived metastatic variant cell lines with phenotypic differences in growth and metastasis should prove useful for dissecting the role of tumor and host factor(s) in malignant transformation and metastatic tumor progression of squamous cell carcinoma.

Entities:  

Mesh:

Year:  1997        PMID: 9247255     DOI: 10.1023/a:1018474910432

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  22 in total

1.  Association of the VLA alpha 6 subunit with a novel protein. A possible alternative to the common VLA beta 1 subunit on certain cell lines.

Authors:  M E Hemler; C Crouse; A Sonnenberg
Journal:  J Biol Chem       Date:  1989-04-15       Impact factor: 5.157

2.  Keratin gene expression in mouse epidermis and cultured epidermal cells.

Authors:  D R Roop; P Hawley-Nelson; C K Cheng; S H Yuspa
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

3.  Immunostimulation of chemical oncogenesis in the mouse.

Authors:  R T Prehn
Journal:  Int J Cancer       Date:  1977-12-15       Impact factor: 7.396

4.  Pecking order among tumor-specific antigens.

Authors:  J L Urban; C Van Waes; H Schreiber
Journal:  Eur J Immunol       Date:  1984-02       Impact factor: 5.532

5.  Murine Pam 212 cutaneous squamous cell carcinoma is nonimmunogenic in normal syngeneic hosts and resistant to immune effector mechanisms.

Authors:  Z Chen; S I Rosten; E M Lord; A A Gaspari
Journal:  Reg Immunol       Date:  1993 Sep-Oct

6.  Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region.

Authors:  D L Van Dyke; M J Worsham; M S Benninger; C J Krause; S R Baker; G T Wolf; T Drumheller; B C Tilley; T E Carey
Journal:  Genes Chromosomes Cancer       Date:  1994-03       Impact factor: 5.006

7.  Allelotype of head and neck squamous cell carcinoma.

Authors:  H Nawroz; P van der Riet; R H Hruban; W Koch; J M Ruppert; D Sidransky
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701

8.  The beta 4 subunit of the integrin family is displayed on a restricted subset of endothelium in mice.

Authors:  S J Kennel; V Godfrey; L Y Ch'ang; T K Lankford; L J Foote; A Makkinje
Journal:  J Cell Sci       Date:  1992-01       Impact factor: 5.285

9.  A novel integrin (alpha E beta 4) from human epithelial cells suggests a fourth family of integrin adhesion receptors.

Authors:  S Kajiji; R N Tamura; V Quaranta
Journal:  EMBO J       Date:  1989-03       Impact factor: 11.598

10.  Inhibition of tumor growth by elimination of granulocytes.

Authors:  L A Pekarek; B A Starr; A Y Toledano; H Schreiber
Journal:  J Exp Med       Date:  1995-01-01       Impact factor: 14.307

View more
  20 in total

1.  The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1alpha, IL-6, GM-CSF, and KC.

Authors:  C W Smith; Z Chen; G Dong; E Loukinova; M Y Pegram; L Nicholas-Figueroa; C Van Waes
Journal:  Clin Exp Metastasis       Date:  1998-10       Impact factor: 5.150

2.  Retinol induces morphological alterations and proliferative focus formation through free radical-mediated activation of multiple signaling pathways.

Authors:  Daniel Pens Gelain; Matheus Augusto de Bittencourt Pasquali; Fernanda Freitas Caregnato; Mauro Antonio Alves Castro; José Claudio Fonseca Moreira
Journal:  Acta Pharmacol Sin       Date:  2012-03-19       Impact factor: 6.150

3.  Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma.

Authors:  Ayman Oweida; Shelby Lennon; Dylan Calame; Sean Korpela; Shilpa Bhatia; Jaspreet Sharma; Caleb Graham; David Binder; Natalie Serkova; David Raben; Lynn Heasley; Eric Clambey; Raphael Nemenoff; Sana D Karam
Journal:  Oncoimmunology       Date:  2017-08-03       Impact factor: 8.110

4.  Hypoxia-induced autophagic response is associated with aggressive phenotype and elevated incidence of metastasis in orthotopic immunocompetent murine models of head and neck squamous cell carcinomas (HNSCC).

Authors:  Nadarajah Vigneswaran; Jean Wu; Anren Song; Ananth Annapragada; Wolfgang Zacharias
Journal:  Exp Mol Pathol       Date:  2011-01-12       Impact factor: 3.362

Review 5.  Sentinel Lymph Node Biopsy: A new approach in the management of head and neck cancers.

Authors:  Deepti Sharma; George Koshy; Sonal Grover; Bhushan Sharma
Journal:  Sultan Qaboos Univ Med J       Date:  2017-03-30

6.  Characterization of spontaneous metastasis in an aggressive breast carcinoma model using flow cytometry.

Authors:  C M Schmidt; S L Settle; J L Keene; W F Westlin; G A Nickols; D W Griggs
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

7.  Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment.

Authors:  Ayman J Oweida; Shilpa Bhatia; Benjamin Van Court; Laurel Darragh; Natalie Serkova; Sana D Karam
Journal:  J Vis Exp       Date:  2019-04-22       Impact factor: 1.355

8.  The Role of the NF-kappaB Transcriptome and Proteome as Biomarkers in Human Head and Neck Squamous Cell Carcinomas.

Authors:  Zhong Chen; Bin Yan; Carter Van Waes
Journal:  Biomark Med       Date:  2008       Impact factor: 2.851

9.  Cav1 suppresses tumor growth and metastasis in a murine model of cutaneous SCC through modulation of MAPK/AP-1 activation.

Authors:  Casey Trimmer; Gloria Bonuccelli; Sanjay Katiyar; Federica Sotgia; Richard G Pestell; Michael P Lisanti; Franco Capozza
Journal:  Am J Pathol       Date:  2012-12-22       Impact factor: 4.307

10.  Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.

Authors:  Ayman Oweida; Mohammad K Hararah; Andy Phan; David Binder; Shilpa Bhatia; Shelby Lennon; Sanjana Bukkapatnam; Benjamin Van Court; Nomin Uyanga; Laurel Darragh; Hyun Min Kim; David Raben; Aik Choon Tan; Lynn Heasley; Eric Clambey; Raphael Nemenoff; Sana D Karam
Journal:  Clin Cancer Res       Date:  2018-07-24       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.